Karyopharm Therapeutics (NASDAQ:KPTI) Releases Quarterly Earnings Results, Misses Expectations By $0.95 EPS

Karyopharm Therapeutics (NASDAQ:KPTI) released its quarterly earnings results on Thursday. The company reported ($2.32) EPS for the quarter, missing the consensus estimate of ($1.37) by ($0.95), FiscalAI reports. The firm had revenue of $33.43 million for the quarter, compared to analyst estimates of $32.19 million.

Here are the key takeaways from Karyopharm Therapeutics’ conference call:

• Myelofibrosis sNDA remains on track for August 2026 under the FDA’s Accelerated Approval pathway, supported by rapid, deep, and sustained spleen-volume responses in the SENTRY trial and constructive FDA discussions.
• If approved, selinexor plus ruxolitinib could become the first approved combination therapy for myelofibrosis, with a potential launch as early as the first quarter of 2027 and estimated U.S. peak annual revenue of approximately $1 billion.
• Liquidity remains a significant risk: Karyopharm had $65.4 million in cash and investments at quarter-end, expects funding only into September 2026, and faces a $16.8 million term-loan payment on September 10 that could trigger a covenant breach without new financing, a waiver, or a strategic transaction.
• The company is reducing investment in endometrial cancer after the XPORT-EC-042 Phase III trial failed to reach statistical significance, while focusing resources on myelofibrosis and multiple myeloma; XPOVIO U.S. revenue nevertheless rose to $30.8 million from $29.7 million year over year.

Karyopharm Therapeutics Price Performance

KPTI traded down $0.07 during trading on Thursday, hitting $1.97. The company’s stock had a trading volume of 1,129,125 shares, compared to its average volume of 974,032. Karyopharm Therapeutics has a twelve month low of $1.80 and a twelve month high of $10.99. The stock has a market cap of $44.53 million, a PE ratio of -0.13 and a beta of 0.89. The firm’s 50 day moving average price is $7.75 and its 200-day moving average price is $7.93.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on KPTI. Weiss Ratings lowered Karyopharm Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 28th. Royal Bank Of Canada reissued an “outperform” rating and issued a $16.00 price target on shares of Karyopharm Therapeutics in a report on Tuesday, July 21st. HC Wainwright downgraded Karyopharm Therapeutics from a “buy” rating to a “negative” rating in a research report on Friday, July 31st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Karyopharm Therapeutics in a research note on Tuesday, June 9th. Finally, Piper Sandler cut their target price on shares of Karyopharm Therapeutics to $7.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $11.50.

Hedge Funds Weigh In On Karyopharm Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Corient Private Wealth LLC purchased a new stake in Karyopharm Therapeutics during the fourth quarter valued at about $74,000. Baird Financial Group Inc. acquired a new position in shares of Karyopharm Therapeutics in the 2nd quarter valued at about $45,000. State Street Corp lifted its stake in shares of Karyopharm Therapeutics by 27.2% in the 4th quarter. State Street Corp now owns 58,942 shares of the company’s stock valued at $434,000 after purchasing an additional 12,600 shares in the last quarter. Tudor Investment Corp ET AL purchased a new stake in shares of Karyopharm Therapeutics during the 4th quarter worth about $95,000. Finally, XTX Topco Ltd purchased a new stake in shares of Karyopharm Therapeutics during the 2nd quarter worth about $56,000. 66.44% of the stock is currently owned by institutional investors and hedge funds.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.